Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum

Clinical Infectious Diseases

Volumn 48, Issue 2, 2009, Pages

  Lachaud, Laurence ^a,b,c   Bourgeois, Nathalie ^b,c   Plourde, Marie ^a   Leprohon, Philippe ^a   Bastien, Patrick ^c   Ouellette, Marc ^a,d  

^a LAVAL UNIVERSITY   (Canada)

^b NÎMES UNIVERSITY HOSPITAL   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; AMPHOTERICIN B; ANTIPROTOZOAL AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC 50; INCIDENCE; LEISHMANIA INFANTUM; LONG TERM CARE; MALE; PARASITE ISOLATION; PRIORITY JOURNAL; PROPHYLAXIS; REINFECTION; RELAPSE; SOUTHERN EUROPE; TREATMENT DURATION; VISCERAL LEISHMANIASIS; AIDS RELATED COMPLEX; ANIMAL; DRUG EFFECT; EUROPE; FOLLOW UP; ISOLATION AND PURIFICATION; PARASITOLOGY; TREATMENT FAILURE; VIROLOGY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; EUROPE; FOLLOW-UP STUDIES; HIV-1; HUMANS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; PARASITIC SENSITIVITY TESTS; TREATMENT FAILURE;

EID: 58749113633     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/595710     Document Type: Article

References (13)

1. Herwaldt BL. Leishmaniasis. Lancet 1999; 354:1191-9.
2. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2:494-501.
3. Murray HW, Berman J, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366:1561-77.
4. Cruz I, Nieto J, Moreno J, Canavate C, Desjeux P, Alvar J. Leishmania/ HIV co-infections in the second decade. Indian J Med Res 2006; 123:357-88.
5. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298-319.
6. del Giudice P, Mary-Krause M, Pradier C, et al. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 2002; 186:1366-70.
7. Russo R, Nigro L, Panarello G, Montineri A. Clinical survey of Leishmania/ HIV co-infection in Catania, Italy: the impact of highly active antiretroviral therapy (HAART). Ann Trop Med Parasitol 2003; 97(Suppl 1):149-55.
8. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003; 97(Suppl 1):3-15.
9. Lira R, Sundar S, Makharia A, et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999; 180:564-7.
10. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006; 3:e162.
11. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 2006; 193:1375-83.
12. Goad LJ, Holz GG, Beach DH. Sterols of Leishmania species: implications for biosynthesis. Mol Biochem Parasitol 1984; 10:161-70.
13. Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006; 43:917-24.